Autoimmune Army: NIH Patents On-the-Spot Immune Cell Fighters
Published Date: 2/20/2026
Notice
Summary
The National Institutes of Health is fixing a small but important detail in their patent license for a new treatment that uses special immune cells to fight autoimmune diseases. This change clarifies how the treatment’s genetic material is delivered, either by non-viral nanoparticles or viral systems. If you want to comment or apply for a license, you’ve got until March 9, 2026, so don’t miss out!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Viral Delivery (Including Lentivirus) Allowed
If you are a company or researcher seeking an exclusive NIH patent license for an anti-CD19 CAR immunotherapy, the NIH corrected the license language so the therapy can be developed using either a non-viral synthetic nanoparticle delivery system or a viral system — the prior exclusion of lentiviral systems was removed. Written comments or license applications must be received by the NCI Technology Transfer Center on or before March 9, 2026 to be considered.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11892 — Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute)
The National Cancer Institute wants your thoughts on a new way to track and locate cancer research samples through their Specimen Resource Locator. This affects researchers and labs who use these samples, aiming to make finding and sharing easier without adding extra costs or delays. You’ve got 60 days to share your feedback and help shape this helpful tool!
2026-11390 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-11367 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting science projects. If you’re involved in cell biology, heart disease, mental health, or cancer research, these reviews could impact your funding timeline and opportunities.
2026-11357 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on July 16, 2026, with some parts open to the public and others closed to protect private info and trade secrets. This meeting affects researchers and grant applicants, as grant reviews will happen behind closed doors. Anyone can watch the open sessions online and send comments up to 15 days before the meeting—no registration needed!
2026-11018 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late June and early July 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10813 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Previous / Next Documents
Previous: 2026-03336 — Center For Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late March 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide which science projects get funding. Researchers applying for grants and the public can expect no changes in timing or money, just careful, private reviews.
Next: 2026-03338 — Government Owned Inventions Available for License: Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1
The National Cancer Institute is offering a new cancer-fighting invention for licensing. This invention uses a special protein from an ancient virus in our DNA to create vaccines that help the immune system attack certain cancers without harming healthy cells. Researchers and companies interested in developing this promising treatment can now partner up to bring it to patients faster.